NanosonicsNNCSF 90 Return-on-Tangible-Equity is 9.07% as of Dec. 2025, which is 12% above its 10-year median of 8.10. GuruFocus rates NNCSF with a GF Score™ of 90/100 and a GF Value™ of $3.56 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 758 Medical Devices & Instruments companies, Nanosonics ranks better than 66.62% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Nanosonics's annualized net income for the quarter that ended in Dec. 2025 was $12.8 Mil. Nanosonics's average shareholder tangible equity for the quarter that ended in Dec. 2025 was $141.3 Mil. Therefore, Nanosonics's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2025 was 9.07%.
The historical rank and industry rank for Nanosonics's Return-on-Tangible-Equity or its related term are showing as below:
NNCSF'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 0.24 Med: 8.1 Max: 36.49
Current: 9.97
During the past 13 years, Nanosonics's highest Return-on-Tangible-Equity was 36.49%. The lowest was 0.24%. And the median was 8.10%.
NNCSF's Return-on-Tangible-Equity is ranked better than 66.62% of 758
companies
in the Medical Devices & Instruments industry
Industry Median: 4.08
vs NNCSF: 9.97
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Nanosonics Return-on-Tangible-Equity Related Terms
Nanosonics Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Nanosonics's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NNCSF vs ISRG, BDX, MDLN: Return-on-Tangible-Equity Comparison
For the Medical Instruments & Supplies subindustry, Nanosonics's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nanosonics Return-on-Tangible-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Nanosonics's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Nanosonics's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Dec. 2025) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 9.07% mean?
Nanosonics (NNCSF) has a Return-on-Tangible-Equity of 9.07% as of Dec. 2025. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Nanosonics and its competitors. This is 12% above median its historical median of 8.10. Over the past decade, Nanosonics' Return-on-Tangible-Equity has ranged from 0.24 to 36.49. According to the industry distribution chart, Nanosonics ranks #253 out of 758 companies in the Medical Devices & Instruments industry, placing it in the top 33.4%.
Is Nanosonics' Return-on-Tangible-Equity too high?
Nanosonics' current Return-on-Tangible-Equity of 9.07% is 12% above median its 10-year median of 8.10. Over the past 10 years, this metric has ranged from a low of 0.24 to a high of 36.49. The Medical Devices & Instruments industry median Return-on-Tangible-Equity is 4.08. Nanosonics' value of 9.07% is 122.3% above this industry median. Based on the distribution chart, Nanosonics ranks #253 out of 758 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Nanosonics has a GF Score™ of 90/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Nanosonics' Return-on-Tangible-Equity compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Nanosonics ranks #253 out of 758 companies for Return-on-Tangible-Equity. This puts Nanosonics in the upper half of its industry. The industry median Return-on-Tangible-Equity is 4.08. Nanosonics' value of 9.07% is 122.3% above this benchmark. Historically, Nanosonics' own Return-on-Tangible-Equity has ranged from 0.24 to 36.49 over the past decade. While the company's 10-year median is 8.10 vs. the industry median of 4.08, Nanosonics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Medical Devices & Instruments company?
The median Return-on-Tangible-Equity among Medical Devices & Instruments companies is 4.08, based on 758 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Nanosonics's current Return-on-Tangible-Equity of 9.07% is 122.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Nanosonics and its competitors. For the Medical Devices & Instruments industry, the median Return-on-Tangible-Equity is 4.08 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nanosonics's current Return-on-Tangible-Equity is 9.07%, which is 12% above median its own 10-year median of 8.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nanosonics stock overvalued right now?
Based on GuruFocus' analysis, Nanosonics (NNCSF) is currently considered Modestly Undervalued. The stock's GF Value™ is $3.56, compared to a current price of $2.55 — trading 28.4% below its estimated fair value. The current Return-on-Tangible-Equity is 9.07%, which is 12% above median its 10-year median of 8.10 and 122.3% above the Medical Devices & Instruments industry median of 4.08. Nanosonics' overall GF Score™ is 90/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Nanosonics (NNCSF), the current Return-on-Tangible-Equity is 9.07% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Nanosonics (NNCSF) Overvalued in 2026?
Based on GuruFocus' analysis, Nanosonics stock appears to be undervalued.
The current stock price of $2.55 is trading 28.4% below its estimated GF Value™ of $3.56.
GuruFocus considers Nanosonics to be Modestly Undervalued.
Key valuation signals for NNCSF:
Return-on-Tangible-Equity: 9.07% (12% above median its 10-year median of 8.10)
GF Value™: $3.56 vs. price of $2.55 (28.4% below fair value)
Industry Position: 122.3% above the Medical Devices & Instruments median (#253 of 758)
No single metric tells the full story. See the NNCSF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Nanosonics is largely a single-product firm, and its Trophon device provides high-level disinfection of ultrasound probes used in semicritical procedures. The patented technology uses low-temperature sonically activated hydrogen peroxide mist suitable for probes sensitive to damage. Automated HLD is increasingly being used as the standard of care globally as it is superior in preventing cross-infection of patients. Nanosonics' revenue consists of capital sales of Trophon units, ongoing consumables sales, and service revenue. By December 2025, there were 38,000 Trophon units installed globally. Market penetration rates range from over 75% in Australia and New Zealand, over 50% in the US to single-digit penetration in Europe, Middle East, and Africa, and elsewhere in the Asia-Pacific region.
90GF Score
Get the complete analysis for NNCSF
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NNCSF has been successfully added to your 
